王罗;贺鹏飞;窦侠;张杰;张伟;魏准;

• 1:深圳北京大学香港科技大学医学中心生物医学研究所
• 2:中国食品药品检定研究院
• 3:北京大学深圳医院皮肤科

摘要(Abstract)：

目的克隆表达屋尘螨(Dermatophagoides pteronyssinus,Derp)第5组变应原Derp 5基因,在E.coli中表达、纯化重组Derp 5蛋白,并分析其血清Ig E反应原性。方法以合成的Derp 5核酸序列为模板进行PCR扩增,产物经双酶切后与载体pCold-TFM连接,构建重组表达质粒pCold-TFM-Derp 5,转化E.coli BL21(DE3),IPTG诱导表达。用镍离子亲和层析柱和凝胶过滤层析柱纯化目的蛋白,尘螨过敏患者血清鉴定其IgE反应原性。结果重组表达质粒pCold-TFM-Derp 5经双酶切、PCR及测序鉴定证明构建正确;在E.coli BL21(DE3)中实现了目的蛋白的可溶性高表达,毎升细菌表达产物经纯化可得到纯度95%以上的Derp 5蛋白约6 mg。纯化的重组Derp 5蛋白与尘螨过敏患者血清IgE有结合活性。结论成功构建了Derp 5原核表达载体,高效表达并纯化了目的蛋白,纯化的重组Derp 5蛋白具有良好的IgE反应原性,为屋尘螨变态反应性疾病的特异性诊断和治疗以及致敏蛋白的进一步研究奠定了基础。

关键词(KeyWords)： 屋尘螨;第5组变应原;原核细胞;基因表达;特异性免疫治疗;反应原性

Abstract:

Keywords:

基金项目(Foundation):

作者(Authors): 王罗;贺鹏飞;窦侠;张杰;张伟;魏准;

DOI: 10.13200/j.cnki.cjb.001748

参考文献(References)：

• [1]PLATTS-MILLS T A,DE WECK A L,et al.Dust mite allergens and asthma-a worldwide problem[J].J Allergy Clin Immunol,1989,83(2 Pt 1):416-427.
• [2]PLATTS-MILLS T A,CHAPMAN M D.Dust mites:immunology,allergic disease,and environmental control[J].J Allergy Clin Immunol,1987,80(6):755-775.
• [3]THOMAS W R.Geography of house dust mite allergens[J].Asian Pac J Allergy Immunol,2010,28(4):211-224.
• [4]MENO K,THORSTED P B,IPSEN H,et al.The crystal structure of recombinant pro Der p 1,a major house dust mite proteolytic allergen[J].J Immunol,2005,175(6):3835-3845.
• [5]DE HALLEUX S,STURA E,VANDERELST L,et al.Threedimensional structure and Ig E-binding properties of mature fully active Der p 1,a clinically relevant major allergen[J].J Allergy Clin Immunol,2006,117(3):571-576.
• [6]MUELLER G A,BENJAMIN D C,RULE G S.Tertiary structure of the major house dust mite allergen Der p 2:sequential and structural homologies[J].Biochemistry,1998,37(37):12707-12714.
• [7]STREMNITZER C,MANZANO-SZALAI K,STARKL P,et al.Epicutaneously applied Der p 2 induces a strong TH 2-biased antibody response in C57BL/6 mice,independent of functional TLR4[J].Allergy,2014,69(6):741-751.
• [8]THOMAS W R,HALES B J.T and B cell responses to HDM allergens and antigens[J].Immunol Res,2007,37(3):187-199.
• [9]GRUCHALLA R S,PONGRACIC J,PLAUT M,et al.Inner city asthma study:relationships among sensitivity,allergen exposure,and asthma morbidity[J].J Allergy Clin Immunol,2005,115(3):478-485.
• [10]NOON L,CANTAB B.Prophylactic inoculation against hay fever[J].Lancet,1911,177(580):1572-1573.
• [11]BOUSQUET J,LOCKEY R,MALLING H J.Allergen immunotherapy:therapeutic vaccines for allergic diseases.A WHO position paper[J].J Allergy Clin Immunol,1998,102(4 Pt1):558-562.
• [12]LARCH魪M.Specific immunotherapy[J].Br Med Bull,2000,56(4):1019-1036.
• [13]GEHLHAR K,SCHLAAK M,BECKER W,et al.Monitoring allergen immunotherapy of pollen-allergic patients:the ratio of allergen-specific Ig G4 to Ig G1 correlates with clinical outcome[J].Clin Exp Allergy,1999,29(4):497-506.
• [14]VAN DEN BROECK W,DERORE A,SIMOENS P.Anatomy and nomenclature of murine lymph nodes:descriptive study and nomenclatory standardization in BALB/c An NCrl mice[J].J Immunol Methods,2006,312(1-2):12-19.
• [15]BREITENEDER H,HASSFELD W,PETTENBURGER K,et al.Isolation and characterization of messenger RNA from male inflorescences and pollen of the white birch(Betula verrucosa)[J].Int Arch Allergy Imminol,1988,87(1):19-24.
• [16]LI Z,ZHANG Y,XU Y H,et al.Advance in research on novel vaccine against dust mite allergens[J].Chin J Biologicals,2016,29(3):312-314.(in Chinese)李喆,张影,徐颖华,等.新型尘螨过敏原疫苗的研究进展[J].中国生物制品学杂志,2016,29(3):312-314.
• [17]CUI Y B,ZHOU Y,WANG N,et al.Expression of the group3 allergen of Dermato phagoides farinae in p ET32a(+)expression vector and its Ig E-binding reactivity[J].J Pathogen Biol,2014,9(11):1012-1015,1019.(in Chinese)崔玉宝,周鹰,王楠,等.应用p ET32a(+)载体表达尘螨变应原Der f 3及其产物Ig E反应性鉴定[J].中国病原生物学杂志,2014,9(11):1012-1015,1019.
• [18]HOFFMANN A,BUKAU B,KRAMER G.Structure and function of the molecular chaperone Trigger Factor[J].Biochim Biophys Acta,2010,1803(6):650-661.
• [19]VALENTA R,CAMPANA R,MARTH K,et al.Allergenspecific immunotherapy:from therapeutic vaccines to prophylactic approaches[J].J Intern Med,2012,272(2):144-157.
• [20]NONY E,BOULEY J,LE MIGNON M,et al.Development and evaluation of a sublingual tablet based on recombinant Bet v 1 in birch pollen-allergic patients[J].Allergy,2015,70(7):795-804.